Lexicon Pharmaceuticals Inc
LXRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.1B
Close$
$-0.39
116.7% downside
Current Fair Value
116.7% downsideOvervalued by 116.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.10 Billion |
|---|---|
| Enterprise Value | $1.06 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.14 |
| Beta | 1.05 |
| Outstanding Shares | 437,653,000 |
Return
| Return on Equity | -35.02% |
|---|---|
| Return on Assets | -24.44% |
| Return on Invested Capital | -24.27% |
Valuation & Multiples
| P/E Ratio | -16.42 |
|---|---|
| PEG | 1.52 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 25.47 |
| Enterprise Value to EBIT | -18.49 |
| Enterprise Value to Net Income | -18 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.05
Average shareholder expectationRevenue Estimate
$3.99 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
$2.83 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 8.29% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.41%▼ 74.39% |
|---|---|
| Total Invested | $61.54M▼ 87.80% |
| Investors Holding | 50▼ 91.00% |
ESG Score
No data